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ABSTRACT 
 
Identification of Knock-Out Genes to Create a Temperature Sensitive Mutation in 
pMR10 Plasmids. (April 2011) 
 
Sarah Katherine Murphy 
Department of Biomedical Science 
Texas A&M University 
 
Research Advisor: Dr. Thomas Ficht 
Department of Veterinary pathology   
 
Brucella spp. is a gram-negative, cocobacillus, non-motile bacteria that causes a 
zoonotic disease called brucellosis.  Cases of brucellosis remain prevalent in Middle 
Eastern countries, and it is the most common laboratory-acquired infection in the United 
States. It typically causes a mild infection but if left untreated it can lead to chronic 
problems in both humans and animals. There is currently no vaccine against brucellosis 
approved for human use; because of its highly communicable nature and global 
prevalence, one is needed. Finding the knock-out genes for temperature sensitivity in a 
broad-host-range plasmid would be an asset in developing a Brucella mutant for use in a 
vaccine. In this study random mutation with hydroxylamine was preformed in vitro on 
the broad host range plasmid pMR10. Mutated plasmids were then transformed into 
DH5-α competent cells and individual colonies were isolated and grown in nutrient 
broth. The broth was stamped onto agar plates and grown at selective (42°C) and non-
selective (37°C	  and	  30°C) temperatures.  The plates were then screened for growth at the 
lower or non-selective temperatures and no growth at higher or selective temperatures. 
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Of the 23,000 colonies screened in the project none were found to be temperature 
sensitive. 
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NOMENCLATURE 
 
CDC Center for Disease Control 
pMR10 Gram-Negative Broad Host Range RK-2 Based Plasmid 
TLR Toll-Like Receptors 
Ts Temperature Sensitive  
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CHAPTER I 
INTRODUCTION 
 
 
Brucellosis: an overview  
The bacterium in genus Brucella was first discovered in 1887 by British army Captain 
David Bruce. He successfully isolated the first sample of what is now known as Brucella 
melintensis from the spleen of a British solider who died from a febrile disease common 
at his post in Malta. Brucella was isolated again in 1897 when Bernhard Bang found 
B.abortus to be the causative agent in cases of spontaneous abortion in cattle. In 1917 
these two pathogens were found to be identical and the bacterium was given the name 
Brucella after Captain Bruce1.   
 
Brucella is a gram-negative, facultative intercellular, non-motility, coccobacillus 
bacteria2. The condition caused by an infection of Brucella spp. is termed brucellosis; it 
is also commonly referred to as Mediterranean fever or Malta fever because of its 
prevalence in the Mediterranean and Middle East. The infection is typically found in 
animals but is communicable to humans making it a zoonotic disease. There are six 
known species of brucella, there classification is based mainly on host preference and 
_______________ 
This thesis follows the style of Nature. 
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pathology: B. melitennsis (sheep and goats), B. abortus (cattle), B. canis (dogs), B. suis 
(swine), B. neotomae (rodents) and B. ovis (sheep)3,4.  
 
Transmission of Brucella to humans is typically through direct contact with an infected 
animal or ingestion of unpasteurized dairy products, but aerosol transmission is also 
possible if the bacterium becomes airborne. Due to it’s highly transmittable nature and 
low dosage needed to establish infection (10 to 100 CFU) Brucella has become the most 
common cause of laboratory-acquired infections and was used in early bioterrorism 
development in the United States. The weapons developed were never used but this led 
the CDC to classify the organism as a class B select agent5.  
 
Pathology  
Clinical symptoms do not occur until 4 to 6 weeks after initial contact with Brucella. 
This extended asymptomatic incubation period is due the organism’s unique interaction 
with the immune system. Once the pathogen enters the body it colonizes local tissue 
without a typical inflammatory response; this occurs because the organism is able to 
evade recognition by the innate immune cells that’s initially respond. Once in the tissue, 
the infection spreads to organs rich in reticuloepithelial tissue (such as spleen, kidney 
and lymph nodes) and joints where it begins to invade and replicate in the host’s 
phagocytic cells. The organism remains evasive from opsinization by the innate immune 
cell because of its altered pathogen-associated molecular patterns (PAMP); which are the 
immune systems method of recognizing foreign cells in the body. These alterations 
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include, an extended lipid a carbon chain so that TLR 4 cannot recognize it, altered 
flagella to evade recognition by TLR5, and O antigens lacking the hydroxyl group 
needed for c3 to bind and start the alternative complement pathway5-8. This continues for 
4 to 6 weeks when the patient begins to show clinical symptoms of an infection. The 
common symptoms of brucellosis in humans are non-specific flu like symptoms that 
include: head ace, anorexia, nausea, back pain, and undulant fever. Infected animals 
experience a more adverse reaction; common symptoms include: abortion, orchitis, 
undulant fever and sterility2. It is considered chronic if the infection persists for six 
months and symptoms evolve to weight loss, nausea, depression and onset arthritis5,9.   
 
Diagnosis and treatment  
Diagnostic techniques to identify brucellosis are commonly serology tests, including 
enzyme linked immunosorbent assay (ELISA) and agglutination tests. These tests are 
useful in clinical setting but can sometime result in false-positives. Cultures made from 
the patient’s blood are the most reliable test but it is a more labor-intensive technique5,10. 
 
Treatment for an infection is a regiment of multiple antibiotics that are capable of 
working intercellularly and in highly acidic environments. The World Health 
Organization has recommended a 6-week regiment of doxycycline and either rifampicin 
or streptomycin5.  
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Vaccines: present and future  
 Eradication attempts to stop the spread of Brucella in both animals and humans have 
been ongoing since it’s identification, the disease has been nearly eradicated in the 
United States but continues to be a problem in areas in Europe and the Middle East. 
There are still as many as 500,000 emerging cases of brucellosis in humans reported 
each year and an even larger number of animal cases11. The numerous reported cases 
coupled with Brucella’s ability for use in bioterrorism make the need for a viable human 
vaccine a pressing issue. Work on finding one has been in progress for years and 
promising advances have been made.  
 
Vaccines have been USDA approved for animal use these include: Strain 19 (B. 
abortus), strain RB15, and strain Rev1 (B. melitensis). When first developed strain 19- 
BA and 104M vaccines were used on human patients in the USSR and China, but 
because of harsh side effects on the patient it was restricted to only animal use3. The 
creation of a live attenuated vaccine that would be strong enough to elicit protective 
immunity against an infection but not cause adverse effects post vaccination would be an 
ideal vaccine for human use.    
 
Making a temperature sensitive mutant  
Temperature sensitive mutants (Ts) are widely used in laboratories for studying the 
genetics behind cell functions, such as DNA replication and protein production. There 
are several published articles detailing the creation of temperature sensitive plasmids and 
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the knock-out genes involved, but none of these publications discuss findings in a broad 
host range plasmid type required for use in Brucella. Finding the knock-out genes to 
induce Ts in a plasmid like pMR10 would be an asset in developing a vaccine for 
brucellosis.  
 
Types of mutagenesis  
There are several procedures that can be used to randomly mutate a plasmid in hopes of 
finding knock-out genes that will induce temperature sensitivity, some are more 
effective then others.  The options I explored included: PCR, UV mutagenesis, chemical 
mutagenesis and cell lines with deficient DNA repair mechanisms.  
 
PCR, UV mutagenesis and repair enzyme deficient cells are all viable options for 
mutagenesis, but based on previous success in other laboratories with hydroxylamine I 
decided it would be the most promising method to use12. The protocol I chose to use was 
in vitro mutagenesis with hydroxylamine (NH2OH). Hydroxylamine causes point 
mutations in DNA by deaminating cytosine to uracil, changing CG base pairs to AT13. 
The type of mutation caused by this mutagen is ideal for random mutation that could 
lead to temperature sensitive knock-outs.  
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Candidate knock-out genes  
A knock-out that will induce instability at higher temperatures will need to be a mutation 
in part of the genome that code for essential cell function, such as cell division, protein 
production or DNA/RNA synthesis. The mutation will have to allow the cell to perform 
normal function at low or permissive temperature but cease to, or reduce, function at 
higher temperatures14. Previous work with Ts mutants have found that these mutations 
are generally in the origin or replication section of the genome, they are generally 
missense mutations that alter some aspect of replication12. Based off of the finding from 
other laboratories I propose that a point mutation in the ori region of pMR10, in the 6004 
to 6715 bp region seen in Figure 1 below, will lead to temperature sensitivity in the 
plasmid. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Map of the pMR10 plasmid genome 
  7 
CHAPTER II 
PLASMID PURIFICATION AND MUTAGENESIS  
 
Introduction  
The method chosen for this study was in vitro mutagenesis with hydroxylamine and 
isopropyl dialysis. This method was chosen due to its previous success in studies over 
genetic engineering and finding temperature sensitive mutants.12,14 Hydroxylamine 
works by causing missense mutations, changing cytosine to uracile, in the DNA. In 
addition, the DNA damage leads to error-prone repair mechanisms in the cell which can 
cause further point mutations in the DNA.13 This type of point mutations is ideal for 
finding a knock-out to cause temperature instability.  
 
Once exposed to hydroxylamine DNA will continue to mutate at a steady rate until it is 
removed from the solution. The removal must be done at a precise time ensure the 
greatest degree of mutation without rendering the plasmid non-functional. Removal of 
the DNA was done with isopropyl precipitation and dialysis because of its ability to 
completely remove the hydroxylamine from the DNA to stop mutation. 
 
Transformation was done into a strain of competent E. coli, used because of its ability to 
harbor a broad host range plasmid used needed for use in Brucella. There are several 
strains of E. coli cells I explored including XL Blue XL-1 Red, DH5-α, HB101 and 
C600. DH5-α was chosen because of its high efficiency rate when used with the Z-
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Competent cell transformations kit; it has the potential to transform 109 colonies per 1ng 
of DNA added to it.15 Because the goal of this study is to screen several thousand 
colonies a high yield competent cell is ideal.  
 
Materials and methods  
 
DNA purification 
 Cells containing pMR10-CMR plasmid were inoculated into 50ml of Luria-Bertani broth 
containing 50µl of chloramphenicol. The culture was incubated overnight at 37°C with 
moderate shaking (200-300rpm). The liquid culture was then used to extract and purify 
pMR10 plasmids following the IsoPureTM Maxi II DNA Purification kit manufacturers 
protocol16. The purified DNA product was then scanned to determine nucleic acid 
concentration and stored in a 2ml microfuge tube at -20°C.  
 
In-vitro mutagenesis 
The plasmid DNA was mutated following the in-vitro mutagenesis with hydroxylamine 
and isopropyl dialysis protocol. The hydroxylamine solution was prepared by mixing 
.35g hydroxylamine hydrochloride with 4.55ml of cold dH2O; then 450µl of 5M sodium 
hydroxide was added drop wise until the pH was 6.7. Then 25ng of purified plasmid was 
added to the solution and it was left to mutate for 18 hours at 37°C. The DNA was then 
precipitated out with ethanol. This was done by dividing DNA solution evenly into two 
2ml microfuge tubes; then adding 2µg of pellet paint, 2.7µl of sodium acetate, 1.4µl of 
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MgCl2 and 1000µl of ethanol to each. The solution was left at -20°C for one hour to 
allow DNA to participate out. It was then centrifuged at 15000 x g for 10 minutes. 
Supernatant was removed and disposed of in hydroxylamine waste and both pellets were 
then washed with 500µl of 70% ethanol and the two tubes were combined. The solution 
was centrifuged a second time at 15000 x g for 10 minutes, the supernatant was disposed 
of the pellet was left to air dry for 15 minutes. The mutated DNA was re-suspended in 
20µl of dH2O and stored in the -20°C freezer until needed.  
 
Cell transformation and Ts screening 
Competent DH5-α cells were formed into Z-CompetentTM cells and then transformed 
with mutated pMR10-CMR plasmids using the Z-Competent E. coli Transformation Kit 
and Buffer SetTM manufacturers protocol15. 50µl of transformed cells were platted onto 
pre-warmed LB + CM agar plates and incubated for 12 to 24 hours at 30°C. The 
colonies formed were then individually picked using sterile toothpicks and inoculated 
into a 300µl well containing LB+CM broth, in a 96 well plate. The well plates were 
incubated for 12 hours at 30°C. After incubating the well plates were stamped onto 6 
LB+CM agar plates, the first 48 (side I) wells on three plate and the second 48 (side II) 
on three plates. The three plates from side I and II were incubated at 30°C, 37°C and 
42°C, respectively. After a 12 to 24 hour incubation period there plates were removed 
and screened for discrepancies in growth between the temperatures.  
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CHAPTER III 
RESULTS 
 
23,000 colonies were screened in the experiment; all were found to be negative for the 
desired phenotype. My goal of 88,700 colonies screened was unfortunately not reached 
in the given time period of the experiment due to several unforeseen issues. A major 
delay in the experiment occurred when switching to a new transformation kit. I 
experienced difficulty getting correct readings from a photospectrometer in the 
laboratory; I had to follow the procedure 3 times before obtaining cells. Also after 
transforming the isolated cells with my mutated plasmid they had extremely low yield. 
The DH5-α one shot preformed competent cell kit I had been using previously was 
yielding 108 colonies per 2µl of mutated DNA whereas the new kit had a yield of 5 to 10 
colonies using the same amount of DNA. After several attempts with the new 
transformations kit I switched back to the one shot kit. Several other minor infractions 
set my project back; this coupled with the time constraint lead me to fall short of my 
goal.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
Making a Brucella mutant using counter-selection is currently in use, but an 
improvement on the system has been proposed. The new method utilizes a temperature 
sensitive plasmid encoding a flippase. In the first step, the gene(s) to be deleted is 
replaced using a construct containing upstream and downstream flanking DNA 
sequences to promote exchange with the genome and an antibiotic resistance marker 
flanked by Frt sites.  The plasmid encoding the flippase is introduced into this 
background and flippase expression results in removal of the resistance gene by excision 
at the Frt sites.  The secondary plasmid is then removed from the organism by simply 
incubating it at a higher temperature. This would be a stark improvement to the laborious 
work involved in counter-selection. Not only would it save time and materials it would 
also leave the organism unmarked, enhancing its use in a vaccine.  
 
Extensive work on finding a temperature sensitive plasmid has been done by other lab 
members prior to the beginning of this project. The focus has mostly been on XL1-Red 
cells, which are E. coli cells lacking the self-repair genes mutS, mutD, and mutT 
increasing the mutation rate 5,000 fold.17 This work found four temperature sensitive 
colonies; but upon further screening it was discovered that the mutation was in the 
antibiotic resistance area of the genome not the desired plasmid maintenance region, this 
growth pattern is illustrated in part A of Figure 2.    
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Work with hydroxylamine had also previously been done. I chose to continue this work 
because it causes the desired mutation type for finding temperature sensitivity, similar to 
XL1-Red cells, illustrated in Figure 3. The previous work with hydroxylamine did not 
screen a high enough volume of colonies to ensure finding a plasmid that is temperature 
sensitive. Therefore, I believed further colony screening was beneficial.  
 
 
 
 
 
 
0%	   50%	   100%	  
Xl1-­‐Red	  
Hydroxylamine	  
Muta%on	  Types	  	  
transi7onal	  	  
transversions	  
dele7on	  	  
inser7on	  	  
A. 
 
B. 
 
Figure 2 Growth Diagram. Part A. shows the undesired 
results of a mutation in region of the genome coding for 
antibiotic resistance. Part B. shows the desired result of a 
mutation in the part of the genome coding for plasmid 
maintenance.  
Figure 3 Mutation Type. Depicts the type of DNA mutation caused 
by hydroxylamine and XL1-Red cells.  
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Using the formula provided below it was determined with 99% confidence that each 
base pair would be mutated at least one time would require the selection and screening 
of at least 4,555 colonies. This figure makes several assumptions that may not be 
consistent with the mutation process.  First, it assumed that each of the base pairs in the 
genome had the same probability (p) of being mutated; second, it assumed that the 
plasmids were mutating at the appropriate rate (averaging 26.394 bp per plasmid). 
Therefore, while the math predicts that in 23,000 colonies the identification of the 
wanted mutant was probable, it was not guaranteed. 
Hydroxylamine was used throughout the experiment but its validity as a mutagen was 
never confirmed. DNA incubated in hydroxylamine for 18 hours should cause 3bp 
mutations per 1000bp, this number is based on the data illustrated in Figure 4. Therefore, 
plasmid pMR10 mutated with this protocol should cause an average of 26.394bp 
mutations per plasmid. This however was not tested in this experiment and it may be a 
source of error. Future experiments will evaluate the mutation rate directly by 
sequencing selected regions of the plasmid to determine whether mutation was occurring 
at the predicted rate. 
 
    
If Yi= the number of times in n plasmid that base pair I mutates then the probability is  
 
P[Y1≥1,Y2≥1,…Y8798≥1]= .99 
[1- (1-P)n]8798 = .99 
n=4555 
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Even though the Ts plasmid was unfortunately not found in this study it laid the 
groundwork for future experiments. I believe the model used will eventually produce a 
temperature sensitive plasmid; a few changes could be made to reduce the time need to 
screen colonies. For example, replica plating of whole plates instead of picking 
individual colonies or increasing mutations in the plasmid by incubating in 
hydroxylamine for longer periods of time could expedite finding the desired mutation. A 
temperature sensitive plasmid would be a valuable asset to the development of a 
Brucella mutant and work should continue to search for one.  
 
 
 
 
Figure 4 Mutation Rate. Shows the number of base 
pair mutations per 1000 base pairs when mutated for 
different lengths of time. 
 
  15 
REFERENCES 
1 Perkins, S. D., Smither, S. J. & Atkins, H. S. Towards a Brucella vaccine for 
humans. FEMS Microbiol Rev 34, 379-394, doi:FMR211 [pii] 
10.1111/j.1574-6976.2010.00211.x (2010). 
2 Corbel, M. J. Brucellosis: an overview. Emerg Infect Dis 3, 213-221 (1997). 
3 Seleem, M. N., Boyle, S. M. & Sriranganathan, N. Brucellosis: a re-emerging 
zoonosis. Vet Microbiol 140, 392-398, doi:S0378-1135(09)00305-8 [pii] 
10.1016/j.vetmic.2009.06.021 (2010). 
4 Glynn, M. K. & Lynn, T. V. Brucellosis. J Am Vet Med Assoc 233, 900-908, 
doi:10.2460/javma.233.6.900 (2008). 
5 Pappas, G., Panagopoulou, P., Christou, L. & Akritidis, N. Brucella as a 
biological weapon. Cell Mol Life Sci 63, 2229-2236, doi:10.1007/s00018-006-
6311-4 (2006). 
6 de Jong, M. F., Rolan, H. G. & Tsolis, R. M. Innate immune encounters of the 
(Type) 4th kind: Brucella. Cell Microbiol 12, 1195-1202, doi:CMI1498 [pii] 
10.1111/j.1462-5822.2010.01498.x (2010). 
7 Skendros, P., Pappas, G. & Boura, P. Cell-mediated immunity in human 
brucellosis. Microbes Infect 13, 134-142, doi:S1286-4579(10)00274-1 [pii] 
10.1016/j.micinf.2010.10.015 (2010). 
8 Yingst, S. & Hoover, D. L. T cell immunity to brucellosis. Crit Rev Microbiol 
29, 313-331, doi:10.1080/713608012 (2003). 
9 Kiczka, W., Szkaradkiewicz, A. & Wolko, K. Immunologic mechanisms in 
chronic brucellosis in humans. I. Cell-mediated immunity in chronic brucellosis. 
Pol Arch Med Wewn 59, 135-141 (1978). 
10 Al Dahouk, S., Tomaso, H., Nockler, K., Neubauer, H. & Frangoulidis, D. 
Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: 
serological tests for brucellosis. Clin Lab 49, 577-589 (2003). 
11 Ficht, T. A., Kahl-McDonagh, M. M., Arenas-Gamboa, A. M. & Rice-Ficht, A. 
C. Brucellosis: the case for live, attenuated vaccines. Vaccine 27 Suppl 4, D40-
43, doi:S0264-410X(09)01215-8 [pii] 
10.1016/j.vaccine.2009.08.058 (2009). 
  16 
12 Hashimoto, T. & Sekiguchi, M. Isolation of temperature-sensitive mutants of R 
plasmid by in vitro mutagenesis with hydroxylamine. J Bacteriol 127, 1561-1563 
(1976). 
13 Maloy, S. R. Localized mutagenesis. Methods Enzymol 421, 42-50, doi:S0076-
6879(06)21006-1 [pii] 
10.1016/S0076-6879(06)21006-1 (2007). 
14 Ben-Aroya, S., Pan, X., Boeke, J. D. & Hieter, P. Making temperature-sensitive 
mutants. Methods Enzymol 470, 181-204, doi:S0076-6879(10)70008-2 [pii] 
10.1016/S0076-6879(10)70008-2 (2010). 
15 Z-Competent E. coli Transformation Kit and Buffer Set protocol, ed Zymo 
Research,1-3 (Orange ). 
16 IsoPure Maxi II Prep DNA Purification Kit, Product Information and Kit 
Protocol, 6 (Denville Scinetific INC.). 
17 Greener, A., Callahan, M., & Jerpseth, B. An Efficient 
RandomMutagenesisTechnique Using an E. coli Mutator Strain. Molecular 
Biotechnology 7, 6, doi:1940616221 (1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  17 
CONTACT INFORMATION 
 
Name: Sarah Katherine Murphy  
Professional Address: c/o Dr. Thomas Ficht  
 Department of Veterinary Pathobiology  
 MS 4467 
 Texas A&M University 
 College Station, TX 77843 
Email Address: smurphy@cvm.tamu.edu  
Education: B.S., Biomedical Science, Texas A&M Universityt      
August 2011 
 Undergraduate Research Scholar  
  
